Inclusion Criteria:

Patients must have:

- advanced solid tumors and have confirmed cMET dysregulation

- at least one measurable lesion as defined by RECIST 1.1.

- recovered from all toxicities related to prior anti-cancer therapies

- adequate organ function

- ECOG performance status (PS) of 0 or 1

Exclusion Criteria:

Patients must not have:

- known hypersensitivity to any of the excipients of INC280 or to benzodiazepines or
known intolerance and hypersensitivity to caffeine

- symptomatic central nervous system (CNS) metastases who are neurologically unstable

- presence or history of carcinomatous meningitis

- history of another primary malignancy that is currently clinically significant or
currently requires active intervention

- Clinically significant, uncontrolled heart diseases, including QTcF 450 ms (male
patients), 460 ms (female patients) on the screening ECG

- Thoracic radiotherapy to lung fields 4 weeks prior to starting INC280

- Major surgery within 4 weeks prior to starting INC280

- Patients receiving unstable or increasing doses of corticosteroids.

- Impairment of GI function or GI disease that may significantly alter the absorption
of INC280

- Patients who have received or consumed, or are expected to receive or consume
midazolam or caffeine-containing products (e.g., tea, coffee, cola), within 2 days
prior to Day 1 and during the whole duration of the DDI phase (i.e., from Day -2 to
Day 12)

Other protocol-defined inclusion/exclusion criteria may apply

Minimum Eligible Age: 18 Years

Maximum Eligible Age: N/A

Eligible Gender: Both